Browsed by
Tag: Surge

Why Citizens Financial Group (CFG) Could Be Positioned for a Surge

Why Citizens Financial Group (CFG) Could Be Positioned for a Surge

Citizens Financial Group, Inc. CFG is a financial institution that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CFG’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Citizens Financial Group could be a solid choice for investors.

Current Quarter Estimates for CFG

In the past 30 days, seven estimates have gone higher for Citizens Financial Group while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 59 cents a share 30 days ago, to 69 cents today, a move of 16.9%.

Current Year Estimates for CFG

Meanwhile, Citizens Financial Group’s current year figures are also looking quite promising, with eight estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing/narrowing from $1.68 per share 30 days ago to $1.90 per share today, an increase of 13.1%.

Citizens Financial Group, Inc. Price and Consensus

Citizens Financial Group, Inc. Price and Consensus

Citizens Financial Group, Inc. price-consensus-chart | Citizens Financial Group, Inc. Quote

Bottom Line

The stock has also started to move higher lately, adding 4.6% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank stocks here.

Zacks’ 2020 Election Stock Report: In addition to the

Read the rest
New Study Reveals 450% Surge in Consumers Texting Main Street Businesses, Restaurants and Salons During COVID-19 Pandemic

New Study Reveals 450% Surge in Consumers Texting Main Street Businesses, Restaurants and Salons During COVID-19 Pandemic

Numa research sees significant boost in conversational commerce

Numa, a leading answering service powered by artificial intelligence (AI) that ensures businesses never miss a call or text, today released its latest research on consumer engagement with Main Street businesses. Its infographic, “COVID-19 Changes How Customers Shop at Main Street Businesses,” illustrates surging demand for conversational commerce among consumers and how businesses are evolving communications to service customers in stores and off premises.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201012005156/en/

STUDY REVEALS 450% SURGE IN CONSUMERS TEXTING MAIN STREET BUSINESSES, RESTAURANTS AND SALONS DURING COVID-19 PANDEMIC. Numa research sees significant boost in conversational commerce. (Graphic: Business Wire)

“Our data, based on actual product usage data from small and medium-sized companies, indicates a shift in customer behavior prompted in large part by the global pandemic and shuttering of businesses,” said Numa Founder and CEO Tasso Roumeliotis. “Even before the crisis, customers had shown a preference for texting with businesses in addition to calling, but over the last several months there has been a dramatic increase in virtual engagement and a desire to communicate across multiple channels.”

Businesses today are not only struggling to meet consumer demand but also to adapt to new operational requirements that bring contactless solutions into the equation. With 98% of all text messages opened and 95% responded to within 3 minutes of being delivered, texting is one of the easiest and most immediate ways for businesses to strengthen consumer relationships—even from afar. Add to that the ability to accommodate curbside pickup and 24/7 communication, which mitigates the impact of limited staff and time away from stores, and businesses immediately possess powerful tools to take them beyond surviving to thriving.

After a deep analysis of user behavior, Numa findings include an increase in

Read the rest
China returns to work with a stock market surge

China returns to work with a stock market surge

Chinese stocks led Asian markets higher on Monday as investors bet on a steady recovery for the world’s No 2 economy, though caution about the fate of economic stimulus negotiations in the United States kept investors wary.



a group of people standing in front of a crowd: A strong rebound in tourist numbers in China as coronavirus cases subside points to a robust economic recovery, analysts say [File: Thomas Peter/Reuters]


© A strong rebound in tourist numbers in China as coronavirus cases subside points to a robust economi…
A strong rebound in tourist numbers in China as coronavirus cases subside points to a robust economic recovery, analysts say [File: Thomas Peter/Reuters]

MSCI’s broadest index of Asia-Pacific shares outside Japan rose 0.8 percent to a two-and-a-half-year high, buoyed by a 2-percent gain in Chinese blue chips and a 1.5-percent rise by Hong Kong’s Hang Seng index. Japan’s Nikkei slipped 0.3 percent as investors fretted about corporate earnings there.

Loading...

Load Error

“If capital is moving on relative growth rates, then China is looking quite attractive,” said Chris Weston, head of research brokerage Pepperstone in Melbourne. Equities are cheap, yields advantageous and the outlook solid, he said.

“From a virus perspective as well, we’re seeing concerns in Europe, while China is considered a quasi-safe haven.”

China has returned from an eight-day mid-autumn festival with investors encouraged by a robust rebound in tourism and ebbing coronavirus cases.

After finding a small number of new cases, Qingdao city said on Monday it would conduct COVID-19 tests for its entire population of more than 9 million people over five days.

Elsewhere, in the US Midwest, infections are at record levels and the World Health Organization is urging fresh curbs for Europe.

Coronavirus aid plans in the US are also in disarray, with the Trump administration on Sunday calling on Congress to pass a stripped-down relief bill while talks on a more comprehensive proposal were again at an impasse.

Futures for the S&P 500 wobbled either side of flat in

Read the rest
The S&P 500 could surge 7% based on this bullish technical analysis pattern, BofA says

The S&P 500 could surge 7% based on this bullish technical analysis pattern, BofA says



a man wearing a suit and tie talking on a cell phone: Traders work on the floor of the NYSE in New York Reuters


© Reuters
Traders work on the floor of the NYSE in New York Reuters

  • A bullish technical analysis pattern suggests that the S&P 500 could jump 7%, Bank of America said in a note on Wednesday.
  • The inverted head and shoulders, a bullish continuation pattern, formed in the S&P 500 during the September selloff.
  • If the S&P 500 manages to decisively break above neckline resistance of 3,430, a measured move price target of 3,640 would be in play, according to the bank.
  • Visit Business Insider’s homepage for more stories.

The S&P 500 is set to surge 7% from Wednesday’s end of trading if the index can manage to decisively close above the 3,430 level.

Loading...

Load Error

That’s according to Bank of America, who observed in a note on Wednesday that an inverse head and shoulders pattern has formed in the index.

The inverse head and shoulders is considered a bullish continuation pattern in technical analysis and is a mirror image of the bearish head and shoulders pattern. 

The inverse pattern is made up of a series of three selloffs that typically occur during a period of market consolidation.

The pattern depicts an initial selloff, followed by a short-lived rally, followed by an even deeper selloff, followed by a short-lived rally, followed by one last selloff that finds a bottom near the same level of the first selloff.

The first and last selloffs represent the “left” and “right shoulder,” respectively, while the second (and deeper) selloff represents the “head” of the inverse head and shoulder pattern.

Read More: A $2.5 billion investment chief highlights the stock-market sectors poised to benefit the most if stimulus is passed after the election – and says Trump ending negotiations doesn’t threaten the economic recovery



histogram: An example of an inverse head and shoulders pattern formed in Roku in early 2019. FreeStockCharts.com


© FreeStockCharts.com
An example of an inverse head and shoulders pattern

Read the rest
Regeneron Shares Surge After Trump Praises COVID Treatment

Regeneron Shares Surge After Trump Praises COVID Treatment

Regeneron Pharmaceuticals  (REGN) – Get Report shares surged higher in pre-market trading Thursday after President Donald Trump praised its coronavirus antibody treatment and the drugmaker said it will seek emergency use authorization from the Food & Drug Administration. 

Regeneron said its REGN-COV2 treatment, a combination of two monoclonal antibodies, is designed to prevent the infectivity of SARS-CoV-2, the virus that causes COVID-19. The group has around 50,000 doses available for public use and said it would have doses available for “300,000 patients in total within the next few months” if the Emergency Use Authorization (EUA) is approved.

President Trump was injected with the treatment last week, according to his physicians, and he claimed in a video released late Wednesday to “feel good immediately” and suggested that “it just me me better. I call that a cure.” 

Regeneron shares were marked 4.6% higher in pre-market trading Thursday to indicate an opening bell price of $619.00 each, a move that would extend the stock’s six-month gain to around 20.8%.

Regeneron’s REGN-COV2, is undergoing a jointly run trial with the National Institute of Allergy and Infectious Diseases, of 2,000 people, as well as a separate study of 2,900 coronavirus patients who are in hospitals and ambulatory settings.

Earlier on Wednesday, Eli Lilly & Co. filed an EUA application with the FDA trial data showing that the experimental antibody, Y-CoV555, met both primary and secondary endpoints. 

The drugmaker had earlier noted that the treatment, which is being manufactured in a joint arrangement with Amgen Inc.  (AMGN) – Get Report. reduced the need for hospitalization and emergency-room visits among patients with moderate coronavirus symptoms.

Eli Lilly said it’s studying several neutralizing antibodes for the prevention and treatment of COVID-19, either in combination with other drugs or as a so-called monotherapy,

Read the rest